New Target for the Treatment of Abdominal Obesity
New target for the treatment of obesity and abdominal obesity by inhibiting the FGFR3 receptor signalling pathway Project ID : 7-2018-4658
Summary of the technology
New target for the treatment of obesity and abdominal obesity by inhibiting the FGFR3 receptor signalling pathway
Project ID : 7-2018-4658
Description of the technology
Abdominal obesity, obesity
Current development stage
Pharmaceutical development: TRL2Hypothesis Formulated
Sponsored Research with an option to License Research Results
Obesity is the leading cause of death in America, and is associated with an increase in chronic diseases like, cardiovascular diseases, hypertension, and metabolic disease involving the liver as well as type 2 diabetes. A recent study has shown a correlation between an overexpression of a specific protein and abdominal obesity, however no follow up studies were carried out to indicate a treatment.
The researcher has identified several inhibitory small molecules that specifically target the overexpressed protein responsible for abdominal obesity. A small molecule therapy would inhibit the proteins and reduce or prevent abdominal obesity.
The researcher is looking for sponsored research funding from a partner to: